Broadfin Capital Initiates New Positions In Corium International Inc (CORI), AMAG Pharmaceuticals Inc. (AMAG) and La Jolla Pharmaceutical Company (LJPC)

In three recent filings,  Kevin Kotler’s Broadfin Capital has revealed adding three companies: Corium International Inc (NASDAQ:CORI), AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and La Jolla Pharmaceutical Company (NASDAQ:LJPCto its equity portfolio.

Kevin Kotler

A new filing with the Securities and Exchange Commission showed that Broadfin Capital currently owns 1.35 million shares of Corium International Inc (NASDAQ:CORI), representing 7.66% of common stock outstanding.

Corium International Inc (NASDAQ:CORI) is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products. Earlier in March, the company filed a registration statement on Form S-1 with for a proposed initial public offering of its common stock and later it priced its IPO of 6.50 million shares of common stock at a price to the public of $8.00 per share. The underwriters have been granted a 30-day option to purchase up to 975,000 additional shares of common stock at the IPO price.

In AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Broadfin Capital owns 1.43 million shares, the stake amasses 6.55% of the common stock. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse in the United States.

Last month, Jacob Gottlieb’s Visium Asset Management disclosed initiating a 1.6 million position in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Adage Capital Management, managed by Phill Gross and Robert Atchinson, held 3.80 million shares of the company at the end of 2013.

In another filing, Broadfin Capital disclosed owning a 5.37% passive stake in La Jolla Pharmaceutical Company (NASDAQ:LJPC). The new position contains around 389,900 common stock shares. La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer.

Earlier this month, the fund revealed a reduced stake in MELA Sciences, Inc (NASDAQ:MELA), owning a total of 9.1 million shares, equal to almost 10% of the common stock, down from over 16% held earlier.

Disclosure: none

Recommended Reading:

Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)

Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO

Broadfin Capital Initiates a Stake in Retrophin Inc (RTRX) Following Its Listing on NASDAQ

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click Here to Read Comments
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!